كتبه وراجعه Prof. Dr. Burak Tatlı، Paediatric Neurologist. للمعلومات فقط — وليس نصيحة طبية.

لم تُترجم هذه الصفحة بعد، وتظهر بالإنجليزية.

Emerging therapy

Magnetic stimulation

rTMS, theta-burst stimulation, TMS

The most clinically established technique on this site — genuinely approved for some uses in older adolescents, and still investigational for most of what it is offered for in children.

Overall evidence in children: in clinical trials

Randomised or controlled trials in children are under way or completed, but the result is not yet settled enough for routine care. Taking part in a registered trial is reasonable; paying for it as an established treatment is not.

Where it stands, condition by condition

The same therapy can be well supported for one problem and completely untested for another. This is the single most common place families are misled.

ConditionEvidenceWhat that means here
Adolescent depression Established careRegulators in some countries have cleared repetitive TMS as an add-on treatment in older adolescents. Approval is specific to that indication, age range and device.
Autism In clinical trialsControlled studies exist and continue. Results are mixed and effects reported are modest; it is not established care.
Cerebral palsy / motor recovery In clinical trialsStudied mainly as an add-on to intensive motor therapy rather than a treatment on its own.
Epilepsy Early research onlyLow-frequency protocols have been explored for focal epilepsy. Evidence is limited, and stimulation parameters matter for safety.

What it is

A coil placed against the scalp produces brief magnetic pulses that induce small electrical currents in the cortex just beneath it. The child is awake; there is no anaesthetic.

Repetitive TMS delivers trains of pulses to shift the excitability of a target area — higher frequencies generally increase it, lower frequencies generally reduce it. Theta-burst protocols achieve similar effects in a much shorter session.

TMS is also used purely as a measurement tool, to map motor pathways. That diagnostic use is well established and should not be confused with treatment.

How it is meant to work

Repeated stimulation is thought to change the strength of synaptic connections — the same plasticity mechanisms that underlie ordinary learning.

That has a practical consequence: stimulation is usually paired with therapy, on the reasoning that it opens a window in which practice is more effective. Stimulation alone, with nothing to practise, has less rationale.

What has actually been tested

  • Repetitive TMS has been cleared by regulators as an adjunctive treatment for depression in older adolescents in some countries — a real approval, for a narrow indication.
  • In autism, controlled studies of several protocols have been published over more than a decade. Some report improvements in repetitive behaviours or executive measures; results are inconsistent and effect sizes modest.
  • In cerebral palsy, the more convincing designs pair stimulation with intensive upper-limb therapy and measure hand function, rather than giving stimulation on its own.
  • Paediatric safety has been examined systematically. Expert consensus work has concluded that, within published parameter limits, TMS is generally well tolerated in children.

What we still do not know

  • Which cortical target and protocol suit which child — site selection is often inferred rather than individualised.
  • How long any effect lasts, and whether maintenance sessions are needed.
  • Whether gains translate into everyday function rather than test scores.
  • Whether findings from adults apply to a brain that is still organising.

Risks and costs

  • Scalp discomfort, headache and transient hearing effects without ear protection are the common ones.
  • Seizure is the serious risk. It is rare, and it is the reason published parameter limits exist and why a child with epilepsy needs the protocol reviewed by their neurologist beforehand.
  • Metallic implants near the head, cochlear implants and certain devices are contraindications that must be checked before the first session.
  • A practical caution: effects are small, so courses tend to be long and repeated, which is expensive.

Questions to ask before you agree

Take this list with you

A centre that is doing good work will welcome these questions and answer them in writing.

  1. What target, frequency, intensity relative to motor threshold, and number of sessions — and do these fall inside published paediatric safety limits?
  2. Does my child have any seizure risk, and who reviewed the protocol for that?
  3. Is stimulation paired with therapy, and which therapy?
  4. What is measured before and after, and when do we decide it is not working?

More in this section

In clinical trials

Stem cell therapy

Several different products share this name. Some are licensed medicines for blood disorders; none is a licensed treatment for cerebral palsy or autism anywhere in the world.

Early research only

Exosomes

The cell-free next step after stem cells, with genuinely interesting laboratory science — and, in children, almost no controlled clinical evidence at all.

Early research only

Muse cells

A distinct cell type with an unusual property — it appears to home to damaged tissue on its own — and an unusually small amount of clinical evidence, almost none of it in children.

Early research only

Photobiomodulation

Non-invasive, painless and inexpensive compared with cell therapies — with small, mostly short studies behind it and a wide gap between what is claimed and what has been shown.

Early research only

Peptide preparations

Two quite different things share this word: prescription neuropeptide preparations used routinely in some countries, and an unregulated wellness trade. Neither has good evidence in children.

Early research only

Medicinal mushrooms and nootropics

A research band worth watching, and a supplement shelf to approach carefully. Some of these compounds have real laboratory interest; almost none has been tested in children with neurological conditions.

Established care

Cannabidiol and cannabis-based products

The one product in this group that became a real medicine — and only for three named epilepsy syndromes. The oil sold in a shop and the licensed solution are not the same thing.